Literature DB >> 17850290

The heart rate-lowering agent ivabradine inhibits the pacemaker current I(f) in human atrial myocytes.

Antoun El Chemaly1, Christophe Magaud, Sylvie Patri, Christophe Jayle, Romain Guinamard, Patrick Bois.   

Abstract

INTRODUCTION: It has been speculated that pacemaker current (I(f)) in human atria could play a role in causing ectopic atrial automaticity. Ivabradine is a novel selective and specific I(f) inhibitor in the sinus node that reduces heart rate without any negative inotropic effect. The aim of the study was to explore possible effects of ivabradine on I(f) in atrial myocytes. METHODS AND
RESULTS: Using patch-clamp technique, we studied effects of ivabradine on I(f) present in atrial myocytes isolated from human right appendages of patients undergoing cardiac surgery. The identification of HCN isoforms was obtained by means of multiplex single-cell RT-PCR. Ivabradine induced a marked concentration and use-dependent I(f) inhibition with an IC50 at steady state of 2.9 microM. Time constant of block development (Tau(on)) decreases with the increase in the ivabradine concentration. Use-dependent inhibition induced by ivabradine (3 microM) was not modified in the presence of cAMP (10 microM) in the pipette solution. Multiplex single-cell RT-PCR indicates that the major HCN gene subtype detected in atria was HCN2. HCN4 is detected weakly and HCN1 is not significantly detected.
CONCLUSIONS: Ivabradine inhibits I(f) current in the nonpacemaker cell with characteristics similar to those described previously in rabbit sinus node cells, but revealed a lesser sensitivity for I(f) recorded in human atrial cell than hHCN4 subunits considered as the major contributors to native f-channels in human sinoatrial node. A potential protection of atrial arrhythmias by ivabradine is discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17850290     DOI: 10.1111/j.1540-8167.2007.00955.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  8 in total

1.  Pleiotropic, heart rate-independent cardioprotection by ivabradine.

Authors:  P Kleinbongard; N Gedik; P Witting; B Freedman; N Klöcker; G Heusch
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

2.  From beat rate variability in induced pluripotent stem cell-derived pacemaker cells to heart rate variability in human subjects.

Authors:  Meital Ben-Ari; Revital Schick; Lili Barad; Atara Novak; Erez Ben-Ari; Avraham Lorber; Joseph Itskovitz-Eldor; Michael R Rosen; Amir Weissman; Ofer Binah
Journal:  Heart Rhythm       Date:  2014-06-02       Impact factor: 6.343

Review 3.  I f inhibition with ivabradine : electrophysiological effects and safety.

Authors:  Irina Savelieva; A John Camm
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias.

Authors:  Maaike Hoekstra; Christine L Mummery; Arthur A M Wilde; Connie R Bezzina; Arie O Verkerk
Journal:  Front Physiol       Date:  2012-08-31       Impact factor: 4.566

5.  Effects of ivabradine on cardiac electrophysiology in dogs with age-related atrial fibrillation.

Authors:  Yao-Dong Li; Yu-Tong Ji; Xian-Hui Zhou; Tao Jiang; Yi-fan Hong; Jin-Xin Li; Qiang Xing; Jian Xiong; Yueerguli Yusufuaji; Bao-Peng Tang
Journal:  Med Sci Monit       Date:  2015-05-16

6.  Angiotensin II promotes differentiation of mouse c-kit-positive cardiac stem cells into pacemaker-like cells.

Authors:  Cheng Xue; Jun Zhang; Zhan Lv; Hui Liu; Congxin Huang; Jing Yang; Ten Wang
Journal:  Mol Med Rep       Date:  2015-01-07       Impact factor: 2.952

Review 7.  Human iPSC-Derived Cardiomyocytes for Investigation of Disease Mechanisms and Therapeutic Strategies in Inherited Arrhythmia Syndromes: Strengths and Limitations.

Authors:  Simona Casini; Arie O Verkerk; Carol Ann Remme
Journal:  Cardiovasc Drugs Ther       Date:  2017-06       Impact factor: 3.727

8.  I(f) blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes.

Authors:  Susanne Scheruebel; Chintan N Koyani; Seth Hallström; Petra Lang; Dieter Platzer; Heinrich Mächler; Karl Lohner; Ernst Malle; Klaus Zorn-Pauly; Brigitte Pelzmann
Journal:  J Mol Cell Cardiol       Date:  2014-02-25       Impact factor: 5.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.